AroCell AB (publ) Year-End Report 2018
21 févr. 2019 02h30 HE | AroCell AB
Word from the CEO ”2018 has been an exciting year for AroCell with several major events. In April, AroCell signed a global non-exclusive license agreement with F. Hoffmann-La Roche Ltd (Roche). Roche...
AroCell AB (publ) Bokslutskommuniké 2018
21 févr. 2019 02h30 HE | AroCell AB
VD-ORD ”2018 har varit ett spännande år för AroCell med flera stora händelser. I april tecknade AroCell ett globalt icke exklusivt licensavtal med F. Hoffmann-La Roche Ltd (Roche). Roche är...
AroCell launches new website
01 févr. 2019 07h32 HE | AroCell AB
Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell. The website...
AroCell lanserar ny hemsida
01 févr. 2019 07h32 HE | AroCell AB
Idag lanserar AroCell sin nya hemsida. Målet med den nya hemsidan är att underlätta för våra kunder, affärspartner och investerare att hitta relevant information om AroCell. Webbplatsen (arocell.com)...
gmi 2018.png
Cancer Biological Therapy Market will expand at 6.8% CAGR to hit $108 Billion by 2024: Global Market Insights, Inc.
10 janv. 2019 06h00 HE | Global Market Insights, Inc
Sellbyville, Delaware, Jan. 10, 2019 (GLOBE NEWSWIRE) -- U.S. cancer biological therapy market dominated North America region and was valued at USD 23.2 billion revenue in 2017. High revenue can...
A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development
11 déc. 2018 02h30 HE | AroCell AB
A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine...
Ny vetenskaplig artikel från AroCell som konfirmerar värdet avTK 210 ELISA som verktyg inom läkemedelsutveckling och pre-klinisk forskning
11 déc. 2018 02h30 HE | AroCell AB
AroCell AB (publ) meddelar idag att en vetenskaplig artikel med titeln ” Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels using AroCell...
AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays
27 nov. 2018 09h00 HE | AroCell AB
AroCell’s Chief Scientific Officer, Professor Staffan Eriksson, presents today new preliminary results from the U-CAN TK1 lymphoma study at the International Society of Oncology Biomarkers (ISOBM) in...
AroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder
27 nov. 2018 09h00 HE | AroCell AB
I samband med ISOBMs kongress (International Society of Oncology Biomarkers) i Hamburg, presenterar idag AroCell’s forskningschef, Staffan Eriksson, nya preliminära kliniska resultat från U-CAN TK1...
Logo (3).png
Cancer Immunotherapy Market Worth $152.83 Billion by 2024 - Exclusive Report by Meticulous Research®
30 oct. 2018 09h18 HE | Meticulous Market Research Pvt. Ltd.
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- According to the latest publication from Meticulous Research®, the global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to...